Agency Information Collection Activities: Proposed Collection; Comment Request, 8260 [C1-2012-2821]
Download as PDF
<![CDATA[
8260
Federal Register / Vol. 77, No. 30 / Tuesday, February 14, 2012 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
References
EPA. 2009. Endocrine Disruptor Screening
Program Test Guidelines. OPPTS 890.1300:
Estrogen Receptor Transcriptional Activation
(Human Cell Line (HeLa-9903)). Washington,
DC: U.S. Environmental Protection Agency.
Available: https://www.regulations.gov/
#!documentDetail;D=EPA-HQ-OPPT-20090576-0006.
ICCVAM. 2011. ICCVAM Test Method
Evaluation Report: The LUMI–CELL® ER
(BG1Luc ER TA) Test Method: An In Vitro
Assay for Identifying Human Estrogen
Receptor Agonist and Antagonist Activity of
Chemicals. Research Triangle Park, NC:
National Institute of Environmental Health
Sciences. Available: https://
iccvam.niehs.nih.gov/methods/endocrine/
ERTA-TMER.htm.
ICCVAM. 2006. Addendum to ICCVAM
Evaluation of In Vitro Test Methods for
Detecting Potential Endocrine Disruptors.
Research Triangle Park, NC: National
Institute of Environmental Health Sciences.
Available: https://iccvam.niehs.nih.gov/docs/
endo_docs/EDAddendFinal.pdf.
ICCVAM. 2003a. ICCVAM Evaluation of In
Vitro Test Methods For Detecting Potential
Endocrine Disruptors: Estrogen Receptor and
Androgen Receptor Binding and
Transcriptional Activation Assays. NIH
Publication No. 03–4503. Research Triangle
Park, NC: National Institute of Environmental
Health Sciences. Available: https://
iccvam.niehs.nih.gov/methods/endocrine/
end_TMER.htm.
ICCVAM. 2002a. Background Review
Document. Current Status of Test Methods
for Detecting Endocrine Disruptors: In Vitro
Estrogen Receptor Transcriptional Activation
Assays. NIH Publication No. 03–4505.
Research Triangle Park, NC: National
Institute of Environmental Health Sciences.
Available: https://iccvam.niehs.nih.gov/
methods/endocrine/end_bckgnd.htm#ERTA.
ICCVAM. 2002b. Background Review
Document. Current Status of Test Methods
for Detecting Endocrine Disruptors: In Vitro
Androgen Receptor Binding Assays. NIH
Publication No. 03–4506. Research Triangle
Park, NC: National Institute of Environmental
Health Sciences. Available: https://
iccvam.niehs.nih.gov/methods/endocrine/
end_bckgnd.htm#ARBnd.
ICCVAM. 2002c. Background Review
Document: Current Status of Test Methods
for Detecting Endocrine Disruptors: In Vitro
Estrogen Receptor Binding Assays. NIH
Publication No. 03–4504. Research Triangle
Park, NC: National Institute of Environmental
Health Sciences. Available: https://
iccvam.niehs.nih.gov/methods/endocrine/
end_bckgnd.htm#ERBnd.
ICCVAM. 2002d. Background Review
Document. Current Status of Test Methods
for Detecting Endocrine Disruptors: In Vitro
Androgen Receptor Transcriptional
Activation Assays. NIH Publication No. 03–
4507. Research Triangle Park, NC: National
Institute of Environmental Health Sciences.
Available: https://iccvam.niehs.nih.gov/
methods/endocrine/end_bckgnd.htm#ARTA.
ICCVAM. 2002e. Expert Panel Evaluation
of the Validation Status of In Vitro Test
Methods for Detecting Endocrine Disruptors:
Estrogen Receptor and Androgen Receptor
VerDate Mar<15>2010
21:57 Feb 13, 2012
Jkt 226001
Binding and Transcriptional Activation
Assays. Expert Panel Final Report. Research
Triangle Park, NC: National Institute of
Environmental Health Sciences. Available:
https://iccvam.niehs.nih.gov/methods/
endocrine/end_EPrpt.htm.
OECD. 2009. Test No 455: The Stably
Transfected Human Estrogen Receptor-alpha
Transcriptional Activation Assay for
Detection of Estrogenic Agonist-Activity of
Chemicals. In: OECD Guidelines for the
Testing of Chemicals, Section 4: Health
Effects. Paris: OECD Publishing. Available:
https://www.oecd-ilibrary.org/environment/
oecd-guidelines-for-the-testing-of-chemicalssection-4-health-effects_20745788.
Rogers JM, Denison MS. 2000.
Recombinant cell bioassays for endocrine
disruptors: Development of a stably
transfected human ovarian cell line for the
detection of estrogenic and anti-estrogenic
chemicals. In Vitro Mol Toxicol 13(1):67–82.
Dated: February 7, 2012.
John R. Bucher,
Associate Director, National Toxicology
Program.
[FR Doc. 2012–3437 Filed 2–13–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier CMS–10421]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Correction
In notice document 2012–2821
appearing on pages 6123–6124 in the
issue of February 7, 2012, make the
following correction:
On page 6124, in the first column, in
the last line, ‘‘April 9, 2012’’ should
read ‘‘April 3, 2012’’.
[FR Doc. C1–2012–2821 Filed 2–13–12; 8:45 am]
BILLING CODE 1505–01–D
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0110]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Medical Device
Reporting: Manufacturer, Importer,
User Facility, and Distributor Reporting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
SUMMARY:
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed extension of
an existing collection of information,
and to allow 60 days for public
comment in response to the notice. This
notice solicits comments on medical
device reporting (MDR); manufacturer,
importer, user facility, and distributor
reporting.
DATES: Submit either electronic or
written comments on the collection of
information by April 16, 2012.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Daniel Gittleson, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
5156, Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
E:\FR\FM\14FEN1.SGM
14FEN1
]]>Agencies
[Federal Register Volume 77, Number 30 (Tuesday, February 14, 2012)]
[Notices]
[Page 8260]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: C1-2012-2821]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[Document Identifier CMS-10421]
Agency Information Collection Activities: Proposed Collection;
Comment Request
Correction
In notice document 2012-2821 appearing on pages 6123-6124 in the
issue of February 7, 2012, make the following correction:
On page 6124, in the first column, in the last line, ``April 9,
2012'' should read ``April 3, 2012''.
[FR Doc. C1-2012-2821 Filed 2-13-12; 8:45 am]
BILLING CODE 1505-01-D
